LL-37 protects rats against lethal sepsis caused by gram-negative bacteria

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 5, 2006, Pages 1672-1679

  Cirioni, Oscar ^a   Giacometti, Andrea ^a,f   Ghiselli, Roberto ^a   Bergnach, Cristina ^b   Orlando, Fiorenza ^c   Silvestri, Carmela ^a   Mocchegiani, Federico ^a   Licci, Alberto ^a   Skerlavaj, Barbara ^b   Rocchi, Marco ^d   Saba, Vittorio ^a   Zanetti, Margherita ^b,e   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c INRCA   (Italy)

^d UNIVERSITY OF URBINO   (Italy)

^e Natl Lab CIB   (Italy)

^f c/o Ospedale Regionale ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; ENDOTOXIN; IMIPENEM; LEUCYLLEUCYGLYCYLASPARTYLPHENYLALANYLPHENYALANYLARGINYLLYSYLSERYLLYSYLGLUTA MYLLYSYLISOLEUCYLGLYCYLLYSYLGLUTAMYLPHENYLALANYLLYSYLARGINYLISOLEUCYLVALYLGLUTAM INYLARGINYLISOLEUCYLLYSYLASPARTYLPHENYLALANYLLEUCINE; PIPERACILLIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ANTIENDOTOXIN ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BLOOD; BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ESCHERICHIA COLI; ESCHERICHIA COLI 0111:B4; ESCHERICHIA COLI ATCC 25922; GRAM NEGATIVE INFECTION; GROWTH INHIBITION; LETHALITY; LIVER; MALE; MESENTERY LYMPH NODE; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; PROTECTION; RAT; SEPSIS; SPLEEN;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CECUM; DISEASE MODELS, ANIMAL; ENDOTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GRAM-NEGATIVE BACTERIA; IMIPENEM; INJECTIONS, INTRAPERITONEAL; MALE; NITRITES; PIPERACILLIN; POLYMYXIN B; RANDOM ALLOCATION; RATS; RATS, WISTAR; SEROTYPING; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646452712     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.50.5.1672-1679.2006     Document Type: Article

References (39)

1. Akashi, S., S. Saitoh, Y. Wakabayashi, T. Kikuchi, N. Takamura, Y. Nagai, Y. Kusumoto, K. Fukase, S. Kusumoto, Y. Adachi, A. Kosugi, and K. Miyake. 2003. Lipopolysaccharidc interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J. Exp. Med. 198:1035-1042.
2. Angus, D. C., W. T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, and M. R. Pinsky. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
3. Bochud, P. Y., and T. Calandra. 2003. Pathogenesis of sepsis: new concepts and implications for future treatment. Br. Med. J. 326:262-266.
4. Boman, H. G. 2003. Antibacterial peptides: basic facts and emerging concepts. J. Int. Med. 254:197-215.
5. Bone, R. C. 1991. Pathophysiology of sepsis. Ann. Intern. Med. 115:457-469.
6. Bowdish, D. M. E., D. J. Davidson, D. P. Speert, and R. E. Hancock. 2004. The human cationic peptide LL-37 induces activation of the extracellular signal-regulated kinase and p38 kinase pathways in primary human monocytes. J. Immunol. 172:3758-3767.
7. Bowdish, D. M. E., D. J. Davidson, M. G. Scott, and R. E. Hancock. 2005. Immunomodulatory activities of small host defense peptides. Antimicrob. Agents Chcmother. 49:1727-1732.
8. Cannon, M. 1987. A family of wound healers. Nature 328:478.
9. De Yang, L., Q. Chen, A. P. Schmidt, G. M. Anderson, J. M. Wang, J. Wooters, J. J. Oppenheim, and O. Chertov. 2000. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemo attract human peripheral blood neutrophils, monocytes, and cells. J. Exp. Med. 192:1069-1074.
10. Diekema, D. J., M. A. Pfaller, R. N. Jones, G. V. Doern, P. L. Winokur, A. C. Gales, H. S. Sader, K. Kugler, and M. Beach. 1999. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin. Infect. Dis. 29:595-607.
11. Drabick, J. J., A. K. Bhattacharjee, D. L. Hoover, G. E. Siber, V. E. Morales, L. D. Young, S. L. Brown, and A. S. Cross. 1998. Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin reagent. Antimicrob. Agents Chemother. 42:583-588.
12. Edgeworth, J. D., D. F. Treacher, and S. J. Eykyn. 1999. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit. Care Med. 27:1421-1428.
13. Giacometti, A., O. Cirioni, R. Ghiselli, C. Bergnach, F. Orlando, G. D'Amato, F. Mocchegiani, C. Silvestri, M. S. Del Prete, B. Skerlavaj, M. Zanetti, V. Saba, and G. Scalise. 2004. The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis. Crit. Care Med. 32:2485-2490.
14. Giacometti, A., O. Cirioni, R. Ghiselli, F. Mocchegiani, G. D'Amato, R. Circo, F. Orlando, B. Skerlavaj, C. Silvestri, V. Saba, M. Zanetti, and G. Scalise. 2004. Cathelicidin peptide sheep mycloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock. Am. J. Respir. Crit. Care Med. 169:187-194.
15. Giacometti, A., O. Cirioni, R. Ghiselli, F. Mocchegiani, G. D'Amato, M. S. Del Prete, F. Orlando, W. Kamysz, J. Łukasiak, V. Saba, and G. Scalise. 2003. Administration of protegrin peptide IB-367 to prevent endotoxin-indueed mortality in bile duct-ligated rats. Gut 52:874-878.
16. Glauser, M. P., G. Zanetti, J. D. Baumgartner, and J. Cohen. 1991. Septic shock: pathogenesis. Lancet 338:732-736.
17. Gough, M., R. E. W. Hancock, and N. M. Kelly. 1996. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immun. 64:4922-4927.
18. Hack, C. E., L. A. Aarden, and L. G. Thijs. 1997. Role of cytokines in sepsis. Adv. Immunol. 66:101-195.
19. Hancock, R. E. W. 2001. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect. Dis. 1:156-164.
20. Hancock, R. E. W., and M. G. Scott. 2000. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. USA 97:856-861.
21. Jaccard, C., N. Troillet, S. Harbarth, G. Zanetti, D. Aymon, R. Schneider, R. Chiolero, B. Ricou, J. Romand, O. Huber, P. Ambrosetti, G. Praz, D. Lew, J. Bille, M. P. Glauser, and A. Cometta. 1998. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob. Agents Chemother. 42:2966-2972.
22. Kumar, A., and R. L. Anel. 2001. Experimental and emerging therapies for sepsis and septic shock. Expert Opin. Investig. Drugs 10:1471-1485.
23. Mallen-St. Clair, J., C. T. Pham, S. A. Villalta, G. H. Caughey, and P. J. Wolters. 2004. Mast cell dipeptidyl peptidase I mediates survival from sepsis. J. Clin. Investig. 113:628-634.
24. Manocha, S., D. Feinstein, A. Kumar, and A. Kumar. 2002. Novel therapies for sepsis: antiendotoxin therapies. Expert Opin. Investig. Drugs 11:1795-1812.
25. Meng, G., M. Rutz, M. Schiemann, J. Metzger, A. Gabriec, R. Shawndner, P. B. Luppa, F. Ebel, D. H. Busch, S. Bauer, H. Wagner, and C. J. Kirschning. 2004. Antagonist antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Investig. 113:1473-1481.
26. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, PA.
27. Oren, Z., J. C. Lerman, H. Gudmundsson, B. Agerberth, and Y. Shai. 1999. Structure and organization of the human peptide LL-37 in phospholipids membranes: relevance to the molecular basis for its non-cell selective activity. Biochem. J. 341:501-513.
28. Oren, Z., and Y. Shai. 1998. Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 47:451-463.
29. Parker, S. J., and P. E. Watkins. 2000. Experimental models of gram-negative sepsis. Br. J. Surg. 88:22-30.
30. Remick, D. G., D. E. Newcomb, G. L. Bolgos, and D. R. Call. 2000. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13:110-116.
31. Sharma, V. K., and R. P. Dellinger. 2003. Recent developments in the treatment of sepsis. Expert Opin. Investig. Drugs 12:139-152.
32. Supajatura, V., H. Ushio, A. Nakao, K. Okumura, C. Ra, and H. Ogawa. 2001. Protective roles of mast cells against enterobacterial infection are mediated by Toll-like receptor 4. J. Immunol. 167:2250-2256.
33. Ulevitch, R. J., and P. S. Tobias. 1999. Recognition of gram-negative bacteria and endotoxin by the innate system. Curr. Opin. Immunol. 11:19-22.
34. Wenzel, R. P., M. R. Pinsky, R. J. Ulevitch, and L. Young. 1996. Current understanding of sepsis. Clin. Infect. Dis. 22:407-413.
35. Wheeler, A. P., and G. R. Bernard. 1999. Treating patients with severe sepsis. N. Engl. J. Med. 340:207-214.
36. Yethon, J. A., and C. Whitfield. 2001. Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria. Curr. Drug Targets Infect. Disord. 1:91-106.
37. Yibin, G., Z. Jiang, Z. Hong, L. Gengfa, W. Liangxi, W. Guo, and L. Yongling. 2005. A synthetized cationic tetradecapeptide from hornet venom kills bacteria and neutralizes lipopolysaccharide in vivo and in vitro. Biochem. Pharmacol. 70:209-219.
38. Zanetti, M. 2004. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol. 75:39-48.
39. Zanetti, M., R. Gennaro, and D. Romeo. 1995. Cathelicidins: a novel protein family with common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 374:1-5.